Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07197866 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 41 sites
  2. Study sites: 40 to 41
  3. Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC to Teva Branded Pharmaceutical Products R&D LLC Trial sites expanded: 36 → 40 locations · Eligibility criteria expanded, about 7 words Show 2 more changesShow less
    • Trial sites expanded: 36 → 40 locations
    • Eligibility criteria expanded, about 7 words
  4. Study sites: 34 to 36v20
  5. Study sites: 32 to 34v19
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 30 to 32v18
  2. Study sites: 29 to 30v17
  3. Study sites: 27 to 29v16
  4. Study sites: 26 to 27v15
  5. Study sites: 25 to 26v14
  1. Trial sites expanded: 22 → 25 locationsv13
  2. Study sites: 20 to 22v12
  3. Study sites: 18 to 20v11
  4. Study sites: 17 to 18v10
  5. Study sites: 15 to 17v9
  6. Trial sites expanded: 11 → 15 locationsv8
  7. Study sites: 9 to 11v7
  8. Trial sites expanded: 5 → 9 locationsv6
  9. Study sites: 3 to 5v5
  10. Study sites: 2 to 3v4
  11. Study sites: 1 to 2v3
  12. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Sep 29, 2025 to Sep 30, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 29, 2025 to Sep 30, 2025
  13. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
Trial Details
NCT Number NCT07197866
Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC
Conditions Multiple System Atrophy
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov